TXG logo

10x Genomics, Inc. Stock Price

NasdaqGS:TXG Community·US$1.4b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 23 Fair Values set on narratives written by author

TXG Share Price Performance

US$11.54
-4.37 (-27.47%)
35.9% undervalued intrinsic discount
US$18.00
Fair Value
US$11.54
-4.37 (-27.47%)
35.9% undervalued intrinsic discount
US$18.00
Fair Value
Price US$11.54
AnalystHighTarget US$18.00
AnalystConsensusTarget US$15.08
AnalystLowTarget US$9.00

TXG Community Narratives

AnalystHighTarget·
Fair Value US$18 35.9% undervalued intrinsic discount

Advanced Genomics Trends Will Unlock Precision Medicine

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AnalystConsensusTarget·
Fair Value US$15.08 23.5% undervalued intrinsic discount

Advanced Genomics Tools Will Shape Future Precision Medicine

0users have liked this narrative
0users have commented on this narrative
16users have followed this narrative
AnalystLowTarget·
Fair Value US$9 28.2% overvalued intrinsic discount

US Funding Cuts And Global Pressures Will Hamper Progress

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative

Recent TXG News & Updates

10x Genomics, Inc. Key Details

US$644.5m

Revenue

US$196.2m

Cost of Revenue

US$448.3m

Gross Profit

US$532.9m

Other Expenses

-US$84.6m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Nov 06, 2025
Earnings per share (EPS)
-0.68
Gross Margin
69.56%
Net Profit Margin
-13.13%
Debt/Equity Ratio
0%

10x Genomics, Inc. Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Flawless balance sheet and good value.

3 Risks
3 Rewards

About TXG

Founded
2012
Employees
1306
CEO
Serge Saxonov
WebsiteView website
www.10xgenomics.com

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the Americas, Europe, the Middle East, Africa, China, and the Asia Pacific. It offers Chromium platform that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; Visium platform includes Spatial Gene Expression, HD Spatial Gene Expression, and Spatial Gene and Protein Expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides; and Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

Market Insight

Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading

U.S. Market Performance

  • 7 Days: -1.3%
  • 3 Months: 7.3%
  • 1 Year: 14.4%
  • Year to Date: 13.5%
Over the last 7 days, the market has dropped 1.3%, driven by a decline of 2.1% in the Financials sector. As for the longer term, the market has actually risen by 14% in the last year. Earnings are forecast to grow by 15% annually. Market details ›